Vernalis plc (LON:VER)‘s stock had its “hold” rating reissued by N+1 Singer in a report issued on Thursday. They currently have a GBX 46 ($0.60) price target on the stock. N+1 Singer’s target price points to a potential upside of 11.16% from the company’s previous close.
Other equities analysts have also issued reports about the company. Panmure Gordon reiterated a “buy” rating and issued a GBX 76 ($0.99) target price on shares of Vernalis plc in a research note on Friday, July 8th. Stifel Nicolaus reiterated a “buy” rating on shares of Vernalis plc in a research note on Friday, June 24th. Canaccord Genuity reiterated a “buy” rating and issued a GBX 84 ($1.10) target price on shares of Vernalis plc in a research note on Friday, July 8th. Finally, Shore Capital reiterated a “house stock” rating on shares of Vernalis plc in a research note on Tuesday, July 19th. One research analyst has rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of GBX 73 ($0.95).
Shares of Vernalis plc (LON:VER) opened at 41.3832 on Thursday. Vernalis plc has a 52-week low of GBX 31.00 and a 52-week high of GBX 79.00. The firm has a 50-day moving average price of GBX 43.63 and a 200-day moving average price of GBX 45.70. The firm’s market cap is GBX 184.21 million.
In other Vernalis plc news, insider Carol Ferguson bought 28,000 shares of the company’s stock in a transaction that occurred on Friday, September 30th. The stock was purchased at an average cost of GBX 41 ($0.54) per share, for a total transaction of £11,480 ($14,984.99).
About Vernalis plc
Vernalis plc is a commercial-stage pharmaceutical holding company. The Company is engaged in the research, development and commercialization of pharmaceutical products for a range of medical disorders. The Company has two marketed products: Tuzistra XR in the United States prescription cough cold market, and frovatriptan, an acute treatment for migraine.
Receive News & Ratings for Vernalis plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vernalis plc and related companies with MarketBeat.com's FREE daily email newsletter.